Clinical trial
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
NCT02520791 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- September 13, 2016
- Completion date
- December 24, 2026
- Enrollment
- 21 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.
advanced primary cutaneous t-cell non-hodgkin lymphoma, recurrent follicular helper t-cell lymphoma, angioimmunoblastic-type, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3a follicular lymphoma, recurrent mature t-cell and nk-cell non-hodgkin lymphoma, recurrent mycosis fungoides, recurrent primary cutaneous t-cell non-hodgkin lymphoma, refractory follicular helper t-cell lymphoma, angioimmunoblastic-type, refractory grade 1 follicular lymphoma, refractory grade 2 follicular lymphoma, refractory grade 3a follicular lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma, stage ib mycosis fungoides ajcc v7, stage ii mycosis fungoides ajcc v7, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii mycosis fungoides ajcc v7, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv mycosis fungoides ajcc v7